SHYNDEC(SH:600420) Xin Lang Cai Jing·2026-01-12 09:06Core Viewpoint - The announcement from China National Pharmaceutical Group Modern indicates that its wholly-owned subsidiary, China National Pharmaceutical Wichida, has received notification that the injectable Piperacillin Sodium in new specifications of 1.0g, 0.5g, and 2.0g has passed the consistency evaluation for generic drugs, which is beneficial for market expansion [1] Group 1: Product Development - The new specifications for Piperacillin Sodium are applicable for various infections, with projected sales in public medical institutions in China reaching approximately 1.906 billion yuan in 2024 [1] - China National Pharmaceutical Wichida has invested approximately 6.12 million yuan in cumulative research and development for this product [1] Group 2: Market Competition - Several other companies have also had products in the same specifications pass or be deemed to have passed the consistency evaluation, indicating a competitive market landscape [1] Group 3: Market Uncertainty - While the new specifications and successful evaluations are advantageous for product market expansion, the sales of the drug are subject to various influencing factors, leading to inherent uncertainties [1]